What is it about?
Introduction: Osteogenesis imperfecta (OI) is a congenital disease comprising a heterogeneous group of inherited connective tissue disorders. The main treatment in children is bisphosphonate therapy. Previous animal studies have shown that bisphosphonates delay tooth eruption. The aim of this study is to determine whether patients with OI treated with pamidronate and/or zoledronic acid have a delayed eruption age compared to a control group of healthy children. Methods: An ambispective longitudinal cohort study evaluating the age of eruption of the first stage mixed dentition in a group of children with OI (n = 37) all treated with intravenous bisphosphonates compared with a group of healthy children (n = 89). Within the study group, the correlation (Pearson correlation test) between the type of medication administered (pamidronate and/or zoledronic acid) and the chronology of tooth eruption is established, as well as the relationship between the amount of cumulative dose received and tooth eruption. Results: The age of eruption of the study group was significantly delayed compared to the age of eruption of the control group for molars and lateral incisors (p < 0.05). Patients who received higher cumulative doses had a delayed eruption age compared to those with lower cumulative doses (p < 0.05). There is a high positive cor relation between age of delayed tooth eruption and Zoledronic acid administration. Conclusion: Patients with OI have a delayed eruption of the 1st stage mixed dentition compared to a control group of healthy children. This delayed eruption is directly related to the cumulative dose of bisphosphonates and the administration of zoledronic ac.
Featured Image
Photo by Ozkan Guner on Unsplash
Why is it important?
Understanding the influence of zoledronic acid and pamidronate on tooth eruption in children with osteogenesis imperfecta (OI) is important for several reasons. OI is a genetic disorder that leads to fragile bones and often results in delayed tooth eruption, impacting a child's oral health and development. This study provides insights into how bisphosphonate treatments affect dental health, helping healthcare providers make informed treatment decisions. The findings indicate that higher doses of bisphosphonates may further delay tooth eruption, which is crucial information for balancing the benefits of improved bone density against potential side effects. Additionally, this research helps parents understand what to expect regarding their child's dental development during treatment. Overall, it contributes to a comprehensive approach to managing OI, ensuring both bone health and dental development are prioritized.
Perspectives
I believe this research is crucial for understanding the dental health challenges faced by children with OI. The study examines how bisphosphonate treatments affect tooth eruption, providing valuable insights for clinicians managing these patients. Our findings emphasize the need to carefully balance the benefits of improved bone density against potential delays in dental development. This research also helps inform parents about what to expect regarding their child's dental health during treatment. Overall, I see this study as an important contribution to a multidisciplinary approach in managing OI, highlighting the integration of dental care into the overall treatment plan to improve health outcomes for affected children.
Prof. Rosa Mourelle
Universidad Complutense de Madrid
Read the Original
This page is a summary of: Influence of zoledronic acid and pamidronate on tooth eruption in children with osteogenesis imperfecta, Bone, May 2024, Elsevier,
DOI: 10.1016/j.bone.2024.117069.
You can read the full text:
Contributors
The following have contributed to this page
